Welcome to our dedicated page for Sotera Health Company news (Ticker: SHC), a resource for investors and traders seeking the latest updates and insights on Sotera Health Company stock.
Sotera Health Company (Nasdaq: SHC) is a leading global provider of sterilization, lab testing, and advisory services, primarily serving the medical device, pharmaceutical, and food industries. The company operates through three main segments: Sterigenics, Nordion, and Nelson Labs. Sterigenics offers terminal sterilization and irradiation services, including gamma and electron beam irradiation, and EO processing. Nordion supplies Co-60 and gamma irradiators, which are critical for the gamma sterilization process. Nelson Labs specializes in outsourced microbiological and analytical chemistry testing.
The company is known for its commitment to ensuring the safety and quality of healthcare products through its comprehensive suite of services. Sotera Health’s lab services cover analytical chemistry, medical device testing, pharmaceutical lab testing, and microbiology testing, helping clients identify and mitigate risks. The advisory segment supports clients in navigating regulatory requirements throughout the product lifecycle.
Recently, Sotera Health has achieved significant milestones, including a 6.7% increase in net revenues for its Sterigenics segment in Q3 2023, driven by favorable pricing and currency exchange rates. Nordion reported a 14.3% increase in net revenues, reflecting robust demand for its services.
Despite challenges, the company has shown resilience, evidenced by a 5.8% increase in third-quarter 2023 net revenues to $263 million. However, a net loss of $14 million was reported due to a $35 million legal settlement. Sotera Health’s ongoing projects include expanding its service offerings and enhancing operational efficiencies.
Headquartered in Cleveland, Ohio, the company had $2.3 billion in total debt and $245 million in cash equivalents as of September 30, 2023, reflecting a strong financial position to support its strategic initiatives. The company continues to focus on its mission of 'Safeguarding Global Health®.'
Sterigenics has officially launched operations at its newly expanded electron beam (E-beam) facility in Columbia City, Indiana. This expansion aims to enhance sterilization services for medical devices and pharmaceutical products, meeting growing customer demands. The installation of a new E-beam accelerator increases sterilization capacity, ensuring safety for healthcare products. Notably, Sterigenics emphasizes improved productivity, reliability, and safety as part of this facility's upgrade, aligning with its mission of Safeguarding Global Health.
Sotera Health Company (Nasdaq: SHC) reported Q1 2022 net revenues of $237 million, a 12% increase from Q1 2021. Net income rose to $31 million or $0.11 per share, compared to $11 million or $0.04 per share last year. Adjusted EBITDA reached $115 million, up by 10%. The company reaffirmed its 2022 financial outlook, expecting net revenues between $1.0 billion and $1.03 billion. Despite challenges like the Omicron surge and geopolitical issues, Sotera Health emphasized strong execution and strategic capacity building.
Sotera Health Company (Nasdaq: SHC) plans to release its financial results for Q1 2022 on May 5, 2022, before market open. A conference call to discuss the results will take place at 9:00 a.m. Eastern Time. Participants can join by dialing 1-866-777-2509 from the U.S. or 1-412-317-5413 internationally. A live webcast of the call will be available on the company’s Investor Relations website, with a replay accessible later on the same day.
Sotera Health Company (Nasdaq: SHC) has launched the Sotera Health Academy, a new educational platform offering over 100 hours of curated content aimed at supporting MedTech and Pharmaceutical customers. The Academy features more than 150 resources, including webinars and eBooks, created by industry experts from Nelson Labs, Sterigenics, and Nordion. This initiative follows Sotera's acquisition of Regulatory Compliance Associates, enhancing the platform's offerings. The Academy aims to help manufacturers navigate regulatory risks and accelerate product market entry.
Sotera Health Company (Nasdaq: SHC) reported a strong financial performance for Q4 2021, with net revenues increasing by 11.3% to $241 million and a net income of $36 million, recovering from a loss of $44 million in the previous year. For the full year, revenues rose 13.9% to $931 million, with net income of $117 million compared to a loss of $39 million in 2020. The company expects 2022 revenue growth of 7% to 11% and plans significant investments in capacity expansions. Total debt stood at $1.8 billion with a net leverage ratio of 3.5x as of December 31, 2021.
Nelson Labs has launched the Nelson Labs Mark, a verification program aimed at enhancing transparency in product testing, particularly for face masks and respirators. This initiative addresses the rise of fraudulent products during the ongoing COVID-19 pandemic, providing consumers and institutions with reliable data on product performance. The program includes two-factor authentication for product verification and will expand to include other products as needed. This effort is part of Nelson Labs' mission to safeguard global health.
Sotera Health Company (Nasdaq: SHC) will announce its financial results for Q4 and full year ended December 31, 2021, on March 1, 2022, before market open. The company is a leading provider of sterilization solutions and lab testing services for healthcare. Following the announcement, a conference call will take place at 9:00 a.m. ET to discuss operating highlights and results. Interested participants can access the call via a dedicated phone line or through a live webcast on the company’s Investor Relations website.
Sotera Health Company (NASDAQ: SHC) has provided an update on its growth and achievements during the 40th Annual J.P. Morgan Healthcare Conference. The company expects its full-year 2021 revenues to reach between $920 million and $930 million, reflecting a growth of approximately 14% from the previous year. CEO Michael B. Petras, Jr. emphasized the company's strong execution throughout 2021 and shared insights on its long-term growth strategy and ESG initiatives. Full financial results for Q4 and year-end 2021 will be reported on March 1, 2022.
Sotera Health Company (NASDAQ: SHC) announced that Chairman and CEO Michael B. Petras, Jr. will present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 7:30 am Eastern. The presentation will provide updates on the company’s diverse businesses focused on end-to-end sterilization solutions and lab testing for healthcare. The management team, including CFO Scott Leffler, will engage in one-on-one meetings with investors. A live webcast can be accessed via the company’s Investor Relations page, and a replay will be available afterward.
Sotera Health Company (Nasdaq: SHC) reported Q3 2021 net revenues of $226 million, up 13.1% from Q3 2020. Net income rose to $27 million or $0.10 per diluted share, compared to $0.01 million in Q3 2020. Adjusted EBITDA increased 16.1% to $117 million, and Adjusted EPS improved to $0.21. Total debt as of September 30, 2021, was $1.78 billion with a net leverage ratio of 3.6x. The company narrowed its full-year revenue outlook to $920 million - $930 million, reflecting 12% - 14% growth.
FAQ
What is the current stock price of Sotera Health Company (SHC)?
What is the market cap of Sotera Health Company (SHC)?
What services does Sotera Health Company offer?
What are the main segments of Sotera Health?
How did Sotera Health perform in the third quarter of 2023?
What are the key components of the gamma sterilization process provided by Nordion?
What financial condition is Sotera Health in as of September 30, 2023?
What recent achievements has Sotera Health made?
Where is Sotera Health headquartered?
What is the company’s mission?
What are Sotera Health’s advisory services focused on?
What recent financial results did Sotera Health announce?
